Committed to environmentally sustainable business practices: Nestle

By: |
New Delhi | Published: June 4, 2016 11:41:34 PM

Nestle India today said it follows environmentally sustainable business practices in its production activities with focus on energy and water conservation.

Nestle India sharesNestle India today said it follows environmentally sustainable business practices in its production activities with focus on energy and water conservation. (Reuters)

Nestle India today said it follows environmentally sustainable business practices in its production activities with focus on energy and water conservation.

“Nestle India is committed to environmentally sustainable business practices at all stages of production making the right choices to protect the future,” it said in a regulatory filing.

The company further said it has “successfully reduced” the generation of greenhouse gas by around 57 per cent and waste water by about 61 per cent in the last 15 years following a series of environmental performance indicators to monitor efforts in sustainability.

“We emphasise on focussed measures for conservation in 2015. Nestle India completed 54 energy reduction projects and 40 water reduction projects across factories, successfully,” Sanjay Khajuria, Senior Vice President, Corporate Affairs, said.

To demonstrate commitment towards reduction in environmental footprint in packaging, Nestle India said it follows specific guidelines on packaging and design and also educates consumers about sustainable consumption.

During 2015, the company used 35 per cent of recycled material in packaging and reduced 800 tonnes of packaging material through packaging optimisation, it added.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Next Stories
1Accident compensation cannot be subjected to TDS: Madras High Court
2Zydus gets FDA nod for phase II clinical trial of Saroglitazar
3Mylan, Biocon confirm efficacy of trastuzumab biosimilar